Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction

Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment, Outcome, and Prognosis Prediction

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03053804

Enrollment

Registered

2017-02-15

Start date

2015-03-31

Completion date

2018-12-31

Last updated

2017-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

MR/PET, Non-small cell lung cancer (NSCLC)

Brief summary

It is a study that hypothesize that MR/PET can have better information than current CT image study, about the medical or surgical treatment outcome of lung cancer

Detailed description

The investigators analyze tumor size、ADCmean、ADCmin、DCE、SUVmax、SUVmin、etc in MR/PET study，to compare its efficacy with other image studies in tumor malignancy grade, systemic involvement detection, treatment outcome after medical target therapy and treatment outcome after surgery.

Interventions

RADIATIONMR/PET

MR/PET with contrast media and FDG-18

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 100 Years

Healthy volunteers

Inclusion criteria

1. Age: \> 20 years old. 2. Patients have confirmed lung cancer by histopathological methods (fiber, bronchoscopy, lung biopsy, open chest biopsy, pleural effusion exfoliated cells, sputum exfoliated cells) 3. Patients voluntarily to join this study and signed informed consents.

Exclusion criteria

1. Any body metal implants (pacemaker implantation, nerve stimulator, vascular stent, aneurysm clip, eye foreign body, the inner metal prosthesis) or artificial heart valves 2. Patients with claustrophobia to MRI examination 3. Patients who are reluctant to comply with follow-up and subsequent examination 4. The other condition that do not meet the inclusion criteria. 5. Pregnancy. 6. Age \< 20 years old.

Design outcomes

Primary

Measure	Time frame
Change from Baseline PET/MR parameters at 2 months after treatment	2 months after treatment

Countries

Taiwan

Contacts

Primary ContactYeun-Chung Chang

ycc5566@ntu.edu.tw02-23123456*65566

Backup ContactYu-Sen Huang

yusen0814@gmail.com02-23123456*65566

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026